Annual rank82
Spain · Healthcare
Clinica Baviera
Ophthalmology-clinic network providing diagnosis, refractive and cataract procedures, specialist treatments and follow-up care for visual disorders.
FY2022–FY2025
FY2022–FY2025
FY2022–FY2025
current context only
Company profile
Eye-care pathways, country brands and a shared clinical platform
At 30 June 2026, Clinica Baviera was a listed specialist eye-care group operating 156 clinics across Spain, Germany, Austria, Italy and the United Kingdom. Three local brands—Baviera, CARE Vision and Optimax—combine laser refractive surgery, intraocular-lens procedures and broader ophthalmology. The network uses smaller consultation and follow-up sites alongside surgical clinics that share equipment, staff and management, supported by doctor training, common protocols and brand-level research.
Laser and lens procedures
One specialist network, several routes beyond glasses
Across the group, corneal-laser options include LASIK, LASEK and Trans-PRK, while lens routes include phakic ICLs and multifocal or monofocal replacements for higher prescriptions, presbyopia and cataracts. Assessment maps prescription, corneal anatomy and eye health before a clinician recommends a route; the offer is specialist surgery, not a single standard product.
- Compare LASIK and LASEK Optimax explains corneal treatment routes and assessment factors
- LASIK procedure CARE Vision's step-by-step outpatient laser pathway
- Trans-PRK A surface-laser route without creation of a corneal flap
- Lens implantation Phakic, multifocal and monofocal lens pathways
- ▶ VideoWatch: an optometrist explains ICL surgery Optimax's English overview of implantable-lens selection
Brands and geography
Three patient-facing names across five countries
At 30 June 2026 the group reported 156 clinics after eight H1 openings: 92 in Spain, 34 in Germany including Vienna, 19 in the United Kingdom and 11 in Italy. Baviera anchors Spain and Italy, CARE Vision serves German-speaking markets, and Optimax adds a British network. These are three patient-facing brands across five countries and four reporting regions, all belonging to one ophthalmology platform.
- Open the current clinic map 156 clinics, eight H1 openings and country counts at 30 June 2026
- CARE Vision within Clinica Baviera The brand relationship and shared ophthalmology scope
- CARE Vision branches German and Austrian consultation and treatment centres
- Optimax story The UK specialist founded in 1991 and acquired in 2024
- Optimax clinic network British locations from London to Scotland and Northern Ireland
- Baviera for international patients English-language coordination for care in Spain
Medical quality and learning
Protocols travel with research, training and named doctors
CARE Vision's R&D team reviews techniques for common protocols, supported by a central medical committee, a European Medical Advisory Board and cooperation with Hamburg-Eppendorf. The wider group uses Baviera Academy, mentoring and competency checks; Optimax publishes its surgeons and treatment technology so readers can inspect the clinical teams and equipment behind the brand.
- Research and medical governance Common protocols, advisory board and Hamburg-Eppendorf work
- CARE Vision doctors Named specialists and their clinical backgrounds
- Optimax technology Diagnostic, laser and lens-surgery equipment
- Optimax surgeons Named consultant ophthalmologists across the UK network
Network organisation
Assessment sites feed shared surgical capacity
The group distinguishes satellite clinics—patient acquisition, pre-operative assessment and follow-up—from surgical clinics with specialised equipment. Management units share people, assets and operational leadership across nearby sites; local contact centres use common scheduling and quality controls. Optimax's founder was also its first patient, an unusual origin for a treatment concept that later became part of a multi-country platform.
- Read the 2025 group report Clinic types, country footprint, training and strategy
- Audited-report library English and statutory group records by year
- A lens-surgery journey Assessment, procedure and follow-up in the UK brand
- ▶ VideoWatch: what happens at a consultation An Optimax ophthalmologist explains services and assessment
Official profile sources: Clínica Baviera Consolidated Management Report 2024 · Baviera — ¿Quiénes somos?
Current 2026 update
What is changing at Clínica Baviera in 2026?
Clínica Baviera is expanding one ophthalmology platform through three patient-facing brands, while new-site timing, cautious German consumers and increased investment in doctor and optometrist availability plus clinic renewal at Optimax create different local tasks.
The change in one sentence
The network is growing, but each reporting region is solving a different operating problem.
Eight H1 openings widened access; the UK is investing in doctor and optometrist availability and clinic renewal; Spain, Italy and Germany/Vienna show different procedure and demand patterns.
Four lenses on 2026
The same four-quadrant format used in the Company profile.
01 · Network states
Eight H1 openings and four named H2 starts must not be mixed
At 30 June the group operated 156 clinics after eight H1 openings: 92 in Spain, 34 in Germany including Vienna, 19 in the UK and 11 in Italy. The Q2 country discussion names six sites at different operating states. Mallorca and Milan are described without the H2 footnote and sit inside the H1 operating story. Segovia, Lorca and Aachen carry a footnote stating that operations begin in H2 and are therefore excluded from the opening page. Rome construction was complete, with activity expected to start in September, and carries the same H2 marker. These six names are not six additions on top of the eight H1 openings. H1 group investment was EUR 6.799 million for openings and relocations and EUR 5.590 million for renovations and improvements; the presentation does not allocate those totals to individual clinics.
- Current signal156 clinics · eight H1 openings · four named H2 starts/plans
- Why it mattersClinic counts become meaningful only when operating sites, completed construction and future starts are kept in separate states.
- H1 clinics and country operations Baviera Group · 29 July 2026
- Clinic and hub-and-spoke model Baviera Group · 27 February 2026
02 · Optimax rebuild
The UK is adding doctor and optometrist availability while renewing clinics
Optimax, the group's UK brand, reported H1 revenue growth of 28%, with positive performance in both laser and intraocular surgery. Its EBITDA contribution remained negative at EUR 1.557 million but improved from a EUR 2.957 million loss. In the same half, the group increased spending to improve the availability of doctors and optometrists and continued a project to renew clinic image and equipment. The issuer reports these developments together but does not say that extra clinical staffing or refurbishment caused the revenue growth or loss reduction. The UK still had 19 clinics at 30 June, so the current change is less about adding addresses than improving capacity and presentation inside the existing brand network. Later evidence must show whether the investment produces durable patient access and operating improvement.
- Current signalRevenue +28% · EBITDA -EUR1.557m · doctors/optometrists and clinic renewal
- Why it mattersOptimax is testing whether better clinical availability and refreshed sites can turn fast demand growth into a sustainable operating platform.
- H1 clinics and country operations Baviera Group · 29 July 2026
- Optimax UK network Optimax · Current official page
03 · Local demand
Spain, Italy and Germany/Vienna are not following one growth script
Spain reported positive trends in both laser and intraocular surgery; openings from 2025 and H1 2026 supplied 25% of its sales increase, while operating leverage and cost discipline supported margin improvement. Italy's positive trend was specifically attributed to laser. Its recent openings contributed about 20% of the sales increase, while Rome-opening costs weighed on the half before the planned September start. Germany including Vienna moved differently: revenue rose only 2%, management described consumers as cautious and savings-oriented with confidence at historic lows, and costs rose faster than sales, reducing EBITDA by 11%. The company says multiple initiatives are underway but does not specify them in the H1 presentation. A shared clinical platform therefore meets distinct procedure mix, opening cycle and consumer-confidence conditions in each reporting region.
- Current signalSpain both procedures positive · Italy laser-led · Germany/Vienna revenue +2%, EBITDA -11%
- Why it mattersLocal demand and procedure mix shape clinic economics, limiting how far group-level growth can be treated as one uniform operating story.
- H1 clinics and country operations Baviera Group · 29 July 2026
- Clinic and hub-and-spoke model Baviera Group · 27 February 2026
04 · What to watch
Three questions for the next disclosures
The next disclosure should show whether pipeline sites and local initiatives become operating evidence.
- H2 clinic startsDo Segovia, Lorca, Aachen and Rome enter operation in H2 and appear in the next clinic count?
- Optimax capacityDoes greater doctor and optometrist availability improve patient access while the UK loss continues to narrow?
- German initiativesWhat actions are actually taken in Germany/Vienna, and do sales and EBITDA respond?
Annual record
Ranking history
Future editions add rows; they do not rewrite the 2026 record.
| Edition | Measurement period | Rank | Revenue growth | Net-income growth | Stock return |
|---|---|---|---|---|---|
| 2026 | FY2022–FY2025 | 82 | +52% | +43% | +225% |